{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:14:17Z","timestamp":1789406057586,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The twice\u2010yearly, long\u2010acting lenacapavir (LA LEN) antiretroviral therapy (ART), when combined with an optimised background regimen, provides a subcutaneous injectable treatment option for people with HIV. This study aimed to understand the preferences, barriers and facilitators for uptake and implementation of LA LEN, with a view to informing clinical implementation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In\u2010depth qualitative interviews and focus groups with purposively sampled people with HIV and healthcare workers (HCWs) from UK HIV services were conducted. Transcripts were analysed using summative and conventional content analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010four people with HIV with varied ART experience were recruited from two HIV services. Participants included 22 (65%) identifying as cisgender men and 12 (35%) identifying as cisgender women; median age was 55\u2009years (range 26\u201376\u2009years). Fourteen HIV HCWs took part in three focus groups. Four key themes and 12 subthemes were identified: LA LEN as a treatment option; LA LEN versus oral ART; switching considerations; and administration of LA LEN. The majority (88%) of people with HIV were interested in switching to LA LEN if offered. Preference was markedly reduced if an oral ART pairing was required. Convenience of the dosing schedule, reduced pill burden and issues around stigma were reasons for interest in LA LEN, but concerns regarding efficacy, dosing interval windows, monitoring and side effects were described. HCWs felt the benefit of LA LEN was as a treatment option for those with adherence issues, drug resistance and a high pill burden. Broader use of LA LEN raised concerns over drug resistance, delivery capacity and storage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LA LEN was viewed as a preferable treatment choice for many people with HIV, provided an all\u2010injectable regimen was available. Feasibility assessments for provision of injectable ART and research on its potential for self\u2010administration are needed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13748","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T04:14:01Z","timestamp":1733890441000},"page":"441-450","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice\u2010yearly injectable <scp>HIV<\/scp> treatment"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-5644","authenticated-orcid":false,"given":"Kate","family":"Alford","sequence":"first","affiliation":[{"name":"Department of Global Health and Infection Brighton and Sussex Medical School  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6435-3444","authenticated-orcid":false,"given":"Shiraaz","family":"Sidat","sequence":"additional","affiliation":[{"name":"Department of Global Health and Infection Brighton and Sussex Medical School  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-217X","authenticated-orcid":false,"given":"Katherine","family":"Bristowe","sequence":"additional","affiliation":[{"name":"Florence Nightingale Faculty of Nursing Midwifery &amp; Palliative Care Cicely Saunders Institute, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6347-966X","authenticated-orcid":false,"given":"Paola","family":"Cicconi","sequence":"additional","affiliation":[{"name":"University Hospitals Oxford NHS Foundation Trust  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-0573","authenticated-orcid":false,"given":"Jamie H.","family":"Vera","sequence":"additional","affiliation":[{"name":"Department of Global Health and Infection Brighton and Sussex Medical School  Brighton UK"},{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-532X","authenticated-orcid":false,"given":"Fiona","family":"Cresswell","sequence":"additional","affiliation":[{"name":"Department of Global Health and Infection Brighton and Sussex Medical School  Brighton UK"},{"name":"University Hospitals Sussex NHS Foundation Trust  Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-021-00750-5"},{"key":"e_1_2_10_3_1","unstructured":"UK Health Security Agency.HIV Testing PrEP New HIV Diagnoses and Care Outcomes for People Accessing HIV Services: 2024 Report.2024."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2126310"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02716-0"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/1413-81232018247.22312017"},{"key":"e_1_2_10_7_1","unstructured":"MurrayCJ BarberRM ForemanKJ et al.Global regional and national disability\u2010adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries 1990\u20132013: quantifying the epidemiological transition. 2015."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2020.1783233"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijph.IJPH_376_18"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad024"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00775-1"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JNC.0000000000000386"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19659"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-016-9827-3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00375-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00113-3"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.011"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01786-0"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_2_10_22_1","unstructured":"Qualtrics. Qualtrics Software. Provo Utah USA.https:\/\/www.qualtrics.com2020."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4135\/9781412963909"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732305276687"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003620"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae331"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.12.214"},{"issue":"2","key":"e_1_2_10_28_1","first-page":"75","article-title":"Long\u2010acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective","volume":"40","author":"Rusconi S","year":"2017","journal-title":"New Microbiol."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_2_10_30_1","unstructured":"OrkinCM HayesR HavilandJ et al.Implementing long\u2010acting cabotegravir\u2009+\u2009rilpivirine therapy in six UK clinics and the community\u2014the ILANA Study. British HIV Association (BHIVA) Spring Conference; Birmingham UK; 2024."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0067"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae125"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0198"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-014-0229-5"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120500330554"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.3.18640"},{"key":"e_1_2_10_37_1","volume-title":"Healthcare Provider Experience of Administering Long\u2010Acting Lenacapavir for People with HIV with Heavy Treatment Experience, Engaged through a Compassionate Use Program in the United States","author":"Herbst AN","year":"2023"},{"key":"e_1_2_10_38_1","unstructured":"HayesR PapariniS MwenderaC OrkinCM.A Longitudinal Qualitative Study of Healthcare Providers' Experiences of Implementing Injectable Cabotegravir and Rilpivirine in England. British HIV Association (BHIVA) Spring Conference; Birmingham UK; 2024."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0126"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0248"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00170-4"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:36:51Z","timestamp":1741757811000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/hiv.13748"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13748","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"2024-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}